71 related articles for article (PubMed ID: 21812539)
1. Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.
Hayden RE; Pratt G; Roberts C; Drayson MT; Bunce CM
Leuk Lymphoma; 2012 Apr; 53(4):537-49. PubMed ID: 21812539
[TBL] [Abstract][Full Text] [Related]
2. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
Haselager MV; Kater AP; Eldering E
Front Oncol; 2020; 10():592205. PubMed ID: 33134182
[TBL] [Abstract][Full Text] [Related]
3. Metabolic reprogramming in the CLL TME; potential for new therapeutic targets.
Simon-Molas H; Montironi C; Kabanova A; Eldering E
Semin Hematol; 2024 Feb; ():. PubMed ID: 38493076
[TBL] [Abstract][Full Text] [Related]
4. Promoting leisure functions through setting creative linguistic landscapes in recreational zones.
Sun K; Tian X; Xia J; Li Q; Hou B
PLoS One; 2024; 19(3):e0299775. PubMed ID: 38517932
[TBL] [Abstract][Full Text] [Related]
5. IPI-145 antagonizes intrinsic and extrinsic survival signals in chronic lymphocytic leukemia cells.
Dong S; Guinn D; Dubovsky JA; Zhong Y; Lehman A; Kutok J; Woyach JA; Byrd JC; Johnson AJ
Blood; 2014 Dec; 124(24):3583-6. PubMed ID: 25258342
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors.
Cheng S; Guo A; Lu P; Ma J; Coleman M; Wang YL
Leukemia; 2015 Apr; 29(4):895-900. PubMed ID: 25189416
[TBL] [Abstract][Full Text] [Related]
7. Evolution of ibrutinib resistance in chronic lymphocytic leukemia (CLL).
Komarova NL; Burger JA; Wodarz D
Proc Natl Acad Sci U S A; 2014 Sep; 111(38):13906-11. PubMed ID: 25201956
[TBL] [Abstract][Full Text] [Related]
8. Update on obinutuzumab in the treatment of B-cell malignancies.
Illidge T; Cheadle EJ; Donaghy C; Honeychurch J
Expert Opin Biol Ther; 2014 Oct; 14(10):1507-17. PubMed ID: 25190612
[TBL] [Abstract][Full Text] [Related]
9. Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
Smith DD; Goldstein L; Cheng M; James DF; Kunkel LA; Fardis M; Hamdy A; Izumi R; Buggy JJ; Clow F
Ann Hematol; 2015 Feb; 94(2):249-56. PubMed ID: 25178517
[TBL] [Abstract][Full Text] [Related]
10. XPO1 inhibition sensitises CLL cells to NK cell mediated cytotoxicity and overcomes HLA-E expression.
Fisher JG; Doyle ADP; Graham LV; Sonar S; Sale B; Henderson I; Del Rio L; Johnson PWM; Landesman Y; Cragg MS; Forconi F; Walker CJ; Khakoo SI; Blunt MD
Leukemia; 2023 Oct; 37(10):2036-2049. PubMed ID: 37528310
[TBL] [Abstract][Full Text] [Related]
11. An agent-based model of monocyte differentiation into tumour-associated macrophages in chronic lymphocytic leukemia.
Verstraete N; Marku M; Domagala M; Arduin H; Bordenave J; Fournié JJ; Ysebaert L; Poupot M; Pancaldi V
iScience; 2023 Jun; 26(6):106897. PubMed ID: 37332613
[TBL] [Abstract][Full Text] [Related]
12. Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL.
Bruch PM; Giles HA; Kolb C; Herbst SA; Becirovic T; Roider T; Lu J; Scheinost S; Wagner L; Huellein J; Berest I; Kriegsmann M; Kriegsmann K; Zgorzelski C; Dreger P; Zaugg JB; Müller-Tidow C; Zenz T; Huber W; Dietrich S
Mol Syst Biol; 2022 Aug; 18(8):e10855. PubMed ID: 35959629
[TBL] [Abstract][Full Text] [Related]
13. Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia.
Burley TA; Hesketh A; Bucca G; Kennedy E; Ladikou EE; Towler BP; Mitchell S; Smith CP; Fegan C; Johnston R; Pepper A; Pepper C
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406371
[TBL] [Abstract][Full Text] [Related]
14. Targeted Drug Delivery for Chronic Lymphocytic Leukemia.
Zoulikha M; He W
Pharm Res; 2022 Mar; 39(3):441-461. PubMed ID: 35257287
[TBL] [Abstract][Full Text] [Related]
15. CCR7 in Blood Cancers - Review of Its Pathophysiological Roles and the Potential as a Therapeutic Target.
Cuesta-Mateos C; Terrón F; Herling M
Front Oncol; 2021; 11():736758. PubMed ID: 34778050
[TBL] [Abstract][Full Text] [Related]
16. Of Lymph Nodes and CLL Cells: Deciphering the Role of CCR7 in the Pathogenesis of CLL and Understanding Its Potential as Therapeutic Target.
Cuesta-Mateos C; Brown JR; Terrón F; Muñoz-Calleja C
Front Immunol; 2021; 12():662866. PubMed ID: 33841445
[TBL] [Abstract][Full Text] [Related]
17. Tissue factor pathway inhibitor upregulates CXCR7 expression and enhances CXCL12-mediated migration in chronic lymphocytic leukemia.
Cui XY; Tjønnfjord GE; Kanse SM; Dahm AEA; Iversen N; Myklebust CF; Sun L; Jiang ZX; Ueland T; Campbell JJ; Ho M; Sandset PM
Sci Rep; 2021 Mar; 11(1):5127. PubMed ID: 33664415
[TBL] [Abstract][Full Text] [Related]
18. LMW-PTP targeting potentiates the effects of drugs used in chronic lymphocytic leukemia therapy.
Capitani N; Lori G; Paoli P; Patrussi L; Troilo A; Baldari CT; Raugei G; D'Elios MM
Cancer Cell Int; 2019; 19():67. PubMed ID: 30948927
[TBL] [Abstract][Full Text] [Related]
19. Precision spherical nucleic acids for delivery of anticancer drugs.
Bousmail D; Amrein L; Fakhoury JJ; Fakih HH; Hsu JCC; Panasci L; Sleiman HF
Chem Sci; 2017 Sep; 8(9):6218-6229. PubMed ID: 28989655
[TBL] [Abstract][Full Text] [Related]
20. HSP90 stabilizes B-cell receptor kinases in a multi-client interactome: PU-H71 induces CLL apoptosis in a cytoprotective microenvironment.
Guo A; Lu P; Lee J; Zhen C; Chiosis G; Wang YL
Oncogene; 2017 Jun; 36(24):3441-3449. PubMed ID: 28114285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
